Royal Bank Of Canada began coverage on shares of Charles River Laboratories International, Inc. (NYSE:CRL) in a research report released on Tuesday morning, Marketbeat Ratings reports. The firm issued a sector perform rating and a $110.00 price objective on the medical research company’s stock.

Other research analysts have also issued reports about the company. Zacks Investment Research upgraded Charles River Laboratories International from a hold rating to a buy rating and set a $111.00 price objective on the stock in a research report on Wednesday, July 12th. Jefferies Group LLC reiterated a buy rating and issued a $121.00 price objective on shares of Charles River Laboratories International in a research report on Friday, June 30th. BidaskClub lowered Charles River Laboratories International from a strong-buy rating to a buy rating in a research report on Monday, July 31st. Robert W. Baird reiterated a buy rating and issued a $114.00 price objective on shares of Charles River Laboratories International in a research report on Friday, September 1st. Finally, Barclays PLC reiterated a hold rating and issued a $102.00 price objective on shares of Charles River Laboratories International in a research report on Wednesday, July 19th. Six research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of Buy and an average target price of $99.59.

Shares of Charles River Laboratories International (CRL) opened at 105.38 on Tuesday. The firm has a market cap of $5.02 billion, a price-to-earnings ratio of 27.77 and a beta of 0.99. Charles River Laboratories International has a one year low of $67.20 and a one year high of $109.59. The stock has a 50 day moving average price of $103.50 and a 200 day moving average price of $95.67.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, August 9th. The medical research company reported $1.29 EPS for the quarter, beating the Zacks’ consensus estimate of $1.22 by $0.07. The firm had revenue of $469.13 million for the quarter, compared to analyst estimates of $458.25 million. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The business’s quarterly revenue was up 8.1% compared to the same quarter last year. During the same period last year, the company earned $1.20 EPS. On average, equities research analysts forecast that Charles River Laboratories International will post $5.10 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was reported by Watch List News and is the property of of Watch List News. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.watchlistnews.com/charles-river-laboratories-international-inc-crl-research-coverage-started-at-royal-bank-of-canada/1580060.html.

In other news, insider Davide Molho sold 5,982 shares of the firm’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $107.55, for a total value of $643,364.10. Following the transaction, the insider now directly owns 22,714 shares in the company, valued at approximately $2,442,890.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David Ross Smith sold 2,552 shares of the firm’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $67.10, for a total value of $171,239.20. Following the completion of the transaction, the insider now owns 11,671 shares in the company, valued at $783,124.10. The disclosure for this sale can be found here. Insiders sold a total of 25,880 shares of company stock worth $2,541,668 over the last 90 days. 2.20% of the stock is owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of the business. Davidson Kempner Capital Management LP bought a new position in Charles River Laboratories International during the second quarter worth about $10,115,000. Lord Abbett & CO. LLC bought a new position in Charles River Laboratories International during the second quarter worth about $65,915,000. WINTON GROUP Ltd bought a new position in Charles River Laboratories International during the second quarter worth about $16,008,000. Public Employees Retirement System of Ohio lifted its holdings in Charles River Laboratories International by 1.5% during the second quarter. Public Employees Retirement System of Ohio now owns 22,383 shares of the medical research company’s stock worth $2,264,000 after acquiring an additional 330 shares in the last quarter. Finally, Koch Industries Inc. bought a new position in Charles River Laboratories International during the second quarter worth about $240,000. Hedge funds and other institutional investors own 95.37% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Analyst Recommendations for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.